New insider activity at Phibro Animal Health ( (PAHC) ) has taken place on February 27, 2025.
Director Thomas E. Corcoran recently made a significant investment in Phibro Animal Health by purchasing 5,000 shares of the company’s stock, amounting to a total value of $110,500.
Recent Updates on PAHC stock
In recent developments, Phibro Animal Health’s stock has seen positive momentum following a strong fiscal Q2 earnings report. The company reported a 24% increase in net sales to $309.3 million and a 64% rise in adjusted EBITDA, driven by the successful integration of the Zoetis Medicated Feed Additive portfolio. This financial performance led Barclays to raise its price target for Phibro from $20 to $22, citing the company’s increased 2025 outlook and the new MFA portfolio as key factors. Despite challenges such as increased SG&A costs and industry concerns like emerging diseases and tariffs, Phibro’s strategic initiatives and optimistic guidance for fiscal year 2025, projecting net sales between $1.25 billion and $1.3 billion, have contributed to a positive outlook. The company’s focus on operational excellence and strategic growth initiatives continues to bolster investor confidence.
More about Phibro Animal Health
YTD Price Performance: 6.61%
Average Trading Volume: 208,621
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $895.1M
Questions or Comments about the article? Write to editor@tipranks.com